Ocugen’s Gene Therapy Trials Light Up Times Square—New Data Offers Hope for Rare Retinal Diseases
Ocugen’s Gene Therapy Trials Light Up Times Square—New Data Offers Hope for Rare Retinal Diseases
AbbVie’s Emraclidine Misses Mark in Schizophrenia Trials—But Safety Signals Keep Hope Alive
Novo Nordisk’s oral obesity drug shows superior efficacy over Eli Lilly’s candidate, reshaping the competitive landscape in metabolic …
With all three Phase 3 trials now enrolling, Akero Therapeutics is racing to bring its promising MASH therapy, …
Facing partnership setbacks and pipeline pressure, Editas Medicine lays off 65% of its staff and pivots toward its …
With a fresh $153 million in funding, Strand Therapeutics is pushing the boundaries of mRNA technology—this time, in …
With a landmark $277 million raise, Element Biosciences is scaling its AVITI™ platform and diving deep into multi-omics—reshaping …
In a surprising move, Novartis snapped up preclinical-stage Kate Therapeutics for over a billion dollars—signaling renewed confidence in …
Despite a muted IPO market and cautious M&A activity, biotech in 2024 proved that innovation never sleeps—especially when …